Pneumococcal Disease Clinical Trial
Official title:
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN IN A SERIES OF 3 INFANT DOSES AND 1 TODDLER DOSE IN INFANTS IN INDIA AND TAIWAN
Verified date | May 2024 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers. This study is enrolling participants who are: - Born after at least 36 weeks of pregnancy and about 2 months of age at the time of entering the study - Have a bodyweight of at least 3 kg Participants will receive either the study vaccine (20vPnC) or a licensed vaccine (13vPnC) as a 4-dose schedule as a shot in the muscle. Participants will receive Dose 1 on study day 1. Dose 2 will be given 28-70 days after Dose 1, and Dose 3 will be given 28-70 days after Dose 2. Dose 4 will be given at 365-455 days (approximately 12-15 months) of age. Participation in the study will take approximately 15 months, during which participants will come to the study clinic for 6 times. The study team will ask questions about the participant's health and take some blood samples during the visit.
Status | Active, not recruiting |
Enrollment | 231 |
Est. completion date | January 24, 2026 |
Est. primary completion date | January 24, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 42 Days to 84 Days |
Eligibility | Inclusion Criteria: - Male or female infants born at =36 weeks of gestation and approximately 2 months of age at the time of consent - Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study - Weight of 3.0 kg or greater at the time of randomization Exclusion Criteria: - History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 13vPnC, 20vPnC, or any other diphtheria toxoid-containing vaccine. - Major known congenital malformation or serious chronic disorder - Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study - Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation. |
Country | Name | City | State |
---|---|---|---|
India | Jawahar Lal Nehru Medical College | Ajmer | Rajasthan |
India | BGS Global Institute of Medical Sciences (BGSGIMS) | Bangalore | Karnataka |
India | Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre | Pune | Maharashtra |
India | Nirmal Hospital Pvt Ltd. | Surat | Gujarat |
Taiwan | Hsinchu Mackay Memorial Hospital | Hsinchu City | Hsinchu |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | Mackay Memorial Hospital | Taipei | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Chang Gung Medical Foundation-Linkou Branch | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
India, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of participants in India and Taiwan with local reactions (redness, swelling, and pain at the injection site), separately by country | Prompted local reactions after each dose | Day 7 | |
Primary | Percentage of participants in India and Taiwan with systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability), separately by country | Prompted systemic reactions after each dose | Day 7 | |
Primary | Percentage of participants in India and Taiwan with adverse events (AEs) from Dose 1 through 1 month after Dose 3 in each group, separately by country | Adverse events occurring from Dose 1 to 1 month after Dose 3 in each group | Dose 1 to 1 month after Dose 3 | |
Primary | Percentage of participants from India and Taiwan with AEs from Dose 4 through 1 month after Dose 4 in each group, separately by country | Adverse events occurring from Dose 4 to 1 month after Dose 4 in each group | Dose 4 to 1 month after Dose 4 | |
Primary | Percentage of participants in India and Taiwan with SAEs from Dose 1 through 1 month after Dose 4 in each group, separately by country | SAEs occurring up to 1 month after Dose 4 in each group | Dose 1 to 1 month after Dose 4 | |
Primary | GMCs of serotype-specific IgG concentrations in Indian participants 1 month after Dose 4 in each vaccine group | IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Indian participants only | 1 month after Dose 4 | |
Secondary | Geometric mean concentrations (GMCs) of serotype-specific IgG concentrations 1 month after Dose 3 in each vaccine group, separately by country | IgG GMCs for the 20vPnC serotypes 1 month after Dose 3 | 1 month after Dose 3 | |
Secondary | Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentration for the 20vPnC serotypes at approximately 1 month after Dose 3 in each vaccine group, separately by country | IgG concentrations for 20vPnC serotypes 1 month after Dose 3 | 1 month after Dose 3 | |
Secondary | GMCs of serotype-specific IgG concentrations in Taiwanese participants 1 month after Dose 4 in each vaccine group | IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Taiwanese participants only | 1 month after Dose 4 | |
Secondary | Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentrations for the 20vPnC serotypes at approximately 1 month after Dose 4 in each vaccine group, separately by country | IgG concentrations for 20vPnC serotypes 1 month after Dose 4 | 1 month after Dose 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546425 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
|
Phase 3 | |
Recruiting |
NCT06044077 -
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
|
Phase 3 | |
Completed |
NCT02146365 -
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
|
||
Completed |
NCT04525599 -
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
|
Phase 1 | |
Completed |
NCT04530838 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
|
Phase 3 | |
Active, not recruiting |
NCT06026748 -
A Phase I Study of XJ103 in Chinese Healthy Subjects
|
Phase 1 | |
Completed |
NCT04526574 -
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
|
Phase 3 | |
Completed |
NCT05329259 -
A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
|
Phase 4 | |
Completed |
NCT00234338 -
Study Evaluating Prevenar in High-Risk Children
|
N/A | |
Completed |
NCT01767402 -
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults
|
Phase 1 | |
Active, not recruiting |
NCT05569954 -
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
|
Phase 3 | |
Completed |
NCT01111214 -
Child Pneumococcal Serotype Epidemiology In Greece
|
N/A | |
Completed |
NCT01298544 -
A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
|
Phase 4 | |
Completed |
NCT04830358 -
Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
|
Phase 1 | |
Completed |
NCT04379713 -
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
|
Phase 3 | |
Completed |
NCT04887948 -
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
|
Phase 3 | |
Completed |
NCT04382326 -
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
|
Phase 3 | |
Not yet recruiting |
NCT00843895 -
Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years
|
N/A | |
Completed |
NCT01734239 -
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
|
Phase 3 | |
Completed |
NCT05408429 -
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
|
Phase 3 |